Rick Bright @RickABright · 07 Jul 2026
🚨📢Vaxart has reported topline safety and efficacy data for their oral COVID-19 vaccine candidate from a 400-person sentinel cohort in their phase 2b trial. These results are a long time coming, after many delays (some of which were absolutely not Vaxart’s fault, eg. temporary https://t.co/uyKtAtwtIw
4 839Views
59Likes
9Reposts
5Replies
2Quotes
0Bookmarks
Is that a lot?
1.60×vs this author's median3 018 views is typical
54Percentile for this authorof 11 recent posts
2.96×vs 10K–100K median1 637 views is typical
9.85%Reachviews ÷ followers
1.55%Engagement rateof viewers reacted